Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > ORGANIZATION
ORGANIZATION
- Scandals Making It Difficult to Recommend Generics to Members: Kyokai Kenpo Chair
April 16, 2021
- Govt Should Set API-by-API Targets for Biosimilars: Society Chief
April 15, 2021
- Hold Off on Nichi-Iko Products for Now to Remove Generic Distrust: Pharmacy Chief
April 9, 2021
- Wakayama Council Makes List of 500 Drugs Commonly Used in Region, Snubs Nichi-Iko/Kobayashi Kako Generics
April 9, 2021
- Industry Group Rolls Out Barcode Reader App for E-Labeling
April 8, 2021
- Generic Industry Group Requests Blanket Manufacturing Checkups for 39 Member Firms
March 31, 2021
- 27.2% Pharmacists Want Total Product Switch from Nichi-Iko to Other Makers, 56.6% Hoping Partial Switch: Survey
March 31, 2021
- Generic Use Rate at 79.4% in October-December 2020: JGA
March 29, 2021
- Industry Group Poised for Pilot Rollout of E-Labeling App in April, Looks to Sales Reps for Popularization
March 26, 2021
- JPMA Renews Call for Post-Launch Innovation Review in 2021 Proposal
March 24, 2021
- Japan Govt Should Change Course on Consistent Price Cuts for On-Patent Drugs: FPMAJ Exec
March 22, 2021
- FPMAJ Adopts FY2021 Project Plans with Focus on Pricing Reform
March 19, 2021
- Trade Groups Push Proper Pricing of Innovative Drugs to Restore Attractiveness of Japan: LDP Confab
March 19, 2021
- With Aducanumab in Mind, Outgoing Chuikyo Payer Rep Floats Rule to Reward Cost Cuts for Pricey Meds
March 18, 2021
- Nichi-Iko Suspended from JGA Membership
March 10, 2021
- Fast-Track Approval System, New Pricing Rules Needed for Therapeutic Apps: DTx Consortium
March 5, 2021
- Ono President Apologizes to JPMA After 2 Employees Are Indicted for Bribery
February 22, 2021
- 76% Sees Healthcare as Top Priority in COVID-19 Response: PhRMA Japan Survey
February 19, 2021
- PhRMA Japan Chief Urges Govt to Return to Pro-Innovation Path, Airs Grievances over Decision-Making on Off-Year Price Cuts
February 19, 2021
- Kobayashi Kako Expelled from JGA over Drug Mix-Up
February 10, 2021
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…